ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

10965	Companies
240137	Keywords
168910	Articles
129233	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 07/08/2024 at 07:56, 2 years 2 months ago

AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19
AB Science annonce des résultats positifs de son étude de phase 2 évaluant le masitinib dans la COVID-19. Les analyses montrent un potentiel traitement prometteur pour les patients hospitalisés

COVID-19 Traitement Étude De Phase 2 AB Science Masitinib
BRIEF

published on 06/28/2024 at 12:36, 2 years 2 months ago

AB Science fait le point sur la demande d'autorisation du masitinib dans la SLA

Autorisation De Mise Sur Le Marché AB Science Masitinib EMA SLA
BRIEF

published on 06/28/2024 at 12:36, 2 years 2 months ago

AB Science provides an update on the application for authorization of masitinib in ALS

ALS AB Science Masitinib EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 12:31, 2 years 2 months ago

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
AB Science annonce un avis négatif sur la demande de mise sur le marché du masitinib dans la SLA et prévoit un réexamen du dossier. Détails sur les raisons et les prochaines étapes

AB Science Masitinib Sclérose Latérale Amyotrophique Autorisation Conditionnelle Réexamen Dossier
PRESS RELEASE

published on 06/28/2024 at 12:31, 2 years 2 months ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations

AB Science Masitinib CHMP ALS Treatment Conditional Marketing Authorization
BRIEF

published on 06/27/2024 at 10:20, 2 years 2 months ago

AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024

Actionnaires Capital Social Assemblée Générale Resolutions AB Science
BRIEF

published on 06/27/2024 at 10:20, 2 years 2 months ago

AB Science - Results of the Combined General Meeting of June 26, 2024

Shareholders Share Capital Resolutions General Assembly AB Science
PRESS RELEASE

published on 06/27/2024 at 10:15, 2 years 2 months ago

AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024
Assemblée Générale Mixte de AB Science du 26 juin 2024 : toutes les résolutions ordinaires et extraordinaires adoptées sauf une. Actionnariat présent : 21.948.183 actions ordinaires et 38.495.615 droits de vote

Actionnaires Droits De Vote Assemblée Générale Resolutions AB Science
BRIEF

published on 05/17/2024 at 18:03, 2 years 3 months ago

Correction des Comptes Consolidés de AB Science pour 2023

Résultats Financiers Recherche Et Développement Comptes Consolidés AB Science Correction Comptable
BRIEF

published on 05/17/2024 at 18:03, 2 years 3 months ago

Correction of the Consolidated Accounts of AB Science for 2023

Financial Results Research And Development Consolidated Accounts AB Science Accounting Correction

Accesswire

Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 57 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago

CGTN: How BRICS creates new opportunities for Global South development

Les Echos

Published on 09/11/2026 at 07:00, 1 day 6 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE